Patient must be NPO for at least 8 hours. Review coagulation profile (INR/platelets). Confirm absence of active anticoagulation therapy. Obtain informed consent. Establish IV access for sedation.
Observe in recovery area for 2-4 hours until sedation wears off. Monitor for signs of perforation or bleeding. Liquid diet permitted after 4 hours. Discharge same day with instructions for soft diet for 48 hours and avoidance of NSAIDs. Follow-up endoscopy as scheduled.
Comprehensive Clinical Guide: Endoscopic Submucosal Dissection (ESD) of the Gastric Antrum
Endoscopic Submucosal Dissection (ESD) represents the gold standard in minimally invasive gastroenterology for the resection of early-stage gastric neoplasms. When localized to the gastric antrum, ESD offers a curative, organ-preserving alternative to traditional surgical gastrectomy. This guide provides an exhaustive clinical overview for medical professionals, detailing the technical, procedural, and post-operative management of antral ESD.
1. Introduction and Overview
Endoscopic Submucosal Dissection (ESD) is an advanced endoscopic technique designed to achieve en bloc resection of superficial gastrointestinal tumors, regardless of their size or shape. Unlike Endoscopic Mucosal Resection (EMR), which is often limited to small lesions due to the "snare-and-cut" mechanism, ESD utilizes specialized electrosurgical knives to dissect the submucosal layer, allowing for the removal of large, flat, or ulcerated gastric lesions in a single piece.
The gastric antrum is a common site for early gastric cancer (EGC) and gastric adenomas. Due to the thicker muscularis propria in the antrum compared to the fundus or corpus, ESD in this region requires specific technical considerations to avoid perforation while ensuring complete oncological resection.
2. Technical Specifications and Mechanism
ESD relies on the creation of a "cushion" between the mucosa and the muscularis propria to provide a safe working space for dissection.
The Procedural Armamentarium
| Equipment | Function |
|---|---|
| High-Definition Endoscope | Provides visualization of vascular patterns and capillary structures. |
| Electrosurgical Unit (ESU) | Provides specific currents (e.g., EndoCut, Swift Coag) for cutting and coagulation. |
| Injection Needles | Used to inject saline/hyaluronic acid to lift the lesion. |
| ESD Knives | (e.g., Dual Knife, IT Knife, Hook Knife) Used for mucosal incision and submucosal dissection. |
| CO2 Insufflation | Essential for reducing post-procedural abdominal distension and pain. |
The Mechanism of Dissection
- Marking: Defining the lateral margins of the lesion with a cautery tip.
- Injection: Submucosal injection of a lifting agent (saline, glycerol, or hyaluronic acid) to create a protective barrier.
- Incision: Circumferential cutting of the mucosa surrounding the lesion.
- Dissection: Progressive tunneling through the submucosal plane using electrocautery until the lesion is entirely detached.
3. Clinical Indications and Usage
ESD is indicated for lesions where the risk of lymph node metastasis is negligible. The Japanese Gastric Cancer Association (JGCA) guidelines remain the global benchmark for these indications.
Absolute Indications
- Differentiated (papillary or tubular) adenocarcinoma, cT1a, without ulceration, regardless of size.
- Differentiated adenocarcinoma, cT1a, with ulceration, ≤ 3 cm.
- Undifferentiated adenocarcinoma, cT1a, without ulceration, ≤ 2 cm.
Expanded Indications
- Differentiated adenocarcinoma, cT1a, without ulceration, > 2 cm.
- Differentiated adenocarcinoma, cT1a, with ulceration, > 3 cm.
- Differentiated adenocarcinoma, cT1b (SM1), ≤ 3 cm.
Patient Selection Criteria
Candidates must be assessed for surgical fitness, anticoagulation status, and the technical accessibility of the antral lesion. Patients with severe coagulopathy or high-risk cardiovascular profiles may require bridging therapy or specialized inpatient management.
4. Pre-Operative Preparation
Preparation is critical to minimize the risk of procedural complications such as aspiration or bleeding.
- Anticoagulation Management: Discontinue antiplatelet agents (e.g., Clopidogrel, Aspirin) and anticoagulants (e.g., Warfarin, DOACs) based on standardized institutional protocols (usually 3-7 days prior).
- Dietary Restrictions: Clear liquid diet 12 hours prior; NPO (nothing by mouth) 8 hours prior to the procedure.
- Sedation: Usually performed under monitored anesthesia care (MAC) or general anesthesia to ensure patient immobilization during the delicate dissection phase.
- Prophylactic Measures: Review of baseline coagulation profiles (INR, PTT, Platelet count).
5. The Procedure: Step-by-Step
The antrum presents unique challenges, including peristaltic motion and proximity to the pylorus.
- Inspection and Mapping: Use Narrow Band Imaging (NBI) or Blue Light Imaging (BLI) to define the lesion boundaries.
- Marking: Use the tip of the knife to create dots 2–3 mm outside the visible margin.
- Submucosal Lifting: Inject fluid (often mixed with indigo carmine/methylene blue and epinephrine) to elevate the lesion.
- Mucosal Incision: Begin with an initial cut on the anal side of the lesion to prevent the "fluid-pooling" effect from obscuring the field.
- Submucosal Dissection: Carefully dissect the submucosa, identifying the "white" fibers of the submucosal layer. Avoid cutting the "red" fibers, which indicate the muscularis propria.
- Hemostasis: Proactive coagulation of visible vessels using the ESD knife or dedicated hemostatic forceps (e.g., Coagrasper).
- Retrieval: The specimen is retrieved using a net or suction for histopathological evaluation.
6. Post-Operative Recovery Protocol
Recovery focus is on preventing delayed hemorrhage and perforation.
- Immediate Post-Op: Monitoring of vitals for signs of perforation (fever, tachycardia, severe abdominal pain).
- Dietary Progression:
- Post-op Day 1: NPO or clear liquids.
- Post-op Day 2-3: Soft diet, transitioning to regular diet as tolerated.
- Pharmacology: Proton Pump Inhibitor (PPI) therapy (IV followed by oral) for 4–8 weeks to facilitate ulcer healing.
- Activity: Avoid heavy lifting or strenuous activity for 7–10 days to minimize the risk of delayed bleeding.
7. Risks, Complications, and Management
While ESD is minimally invasive, it carries specific risks:
| Complication | Incidence | Management |
|---|---|---|
| Bleeding (Intra/Delayed) | 2–5% | Hemostatic clips, coagulation forceps, or repeat endoscopy. |
| Perforation | < 1% | Immediate closure with clips; if large, surgical consultation. |
| Stricture | Rare in antrum | Balloon dilation or stent placement if necessary. |
| Aspiration Pneumonia | < 1% | Respiratory support and prophylactic antibiotics. |
8. Alternative Treatments
- Surgical Gastrectomy: The standard of care for deeper invasions (T1b or T2+).
- Endoscopic Mucosal Resection (EMR): Suitable only for small, benign-appearing polyps (< 10mm).
- Radiofrequency Ablation (RFA): Rarely used in the stomach; usually reserved for Barrett’s esophagus.
9. Massive FAQ Section
1. How long does an antral ESD take?
Typically 60–120 minutes, depending on the size and degree of fibrosis of the lesion.
2. Is ESD painful for the patient?
No, the procedure is performed under deep sedation or general anesthesia. Post-procedural discomfort is usually mild and managed with analgesics.
3. What is the success rate of ESD?
En bloc resection rates exceed 90–95%, with complete (R0) resection rates between 85–90% in expert centers.
4. When can a patient return to work?
Most patients can return to non-strenuous work within 3–5 days.
5. What are the signs of a post-ESD perforation?
Severe, persistent abdominal pain, rigid abdomen, fever, and tachycardia. This is a medical emergency.
6. Why is PPI therapy necessary post-procedure?
The large artificial ulcer created by ESD requires acid suppression to prevent chemical irritation and promote rapid healing, preventing delayed bleeding.
7. Can ESD be performed on patients taking blood thinners?
Yes, but they require a structured "bridge" strategy, often involving consultation with a cardiologist or hematologist.
8. What happens if the pathology shows a positive margin?
If R0 (complete) resection is not achieved, a secondary ESD, surgical resection, or close surveillance may be recommended depending on the histology.
9. How is the antrum different from other stomach regions?
The antrum has a thicker muscular wall, which makes it slightly more resistant to perforation compared to the fundus, but it is also more prone to peristaltic interference during the procedure.
10. Does ESD prevent future gastric cancer?
ESD removes the existing lesion, but it does not treat the underlying "field cancerization" of the stomach. Patients require ongoing surveillance endoscopy.
10. Conclusion
ESD of the gastric antrum is a sophisticated, highly effective procedure that has revolutionized the management of early gastric neoplasia. Success is predicated on rigorous patient selection, meticulous technical execution, and a robust post-operative recovery plan. For clinical teams, maintaining proficiency in hemostasis and understanding the nuances of the gastric wall layers are the two most critical factors in ensuring optimal patient outcomes.
Disclaimer: This guide is for educational purposes for medical professionals. Clinical decisions should always be based on the latest regional guidelines and the individual patient's clinical presentation.